Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Net Income
Bottom-line profit after all expenses, interest, and taxes.
Evommune, Inc.NYSE: EVMN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$21.67M, compared with -$14.56M a year earlier. Trailing-twelve-month net income was -$75.99M.
Context
- Net income amounted to 529.8% of revenue in FY2025, down 424.6 pp from a year earlier.
- Net income grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$20.01M (+70.9%) for the fiscal year ending Dec 2026, a step up from the -3.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.67M+23.3% QoQ
- Last fiscal yearDec 2025
- -$68.87M-3.1% YoY
- LTMMar 2026
- -$75.99M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.9% | -77.9% | -29.1 pp |
| 1 year | -3.1% | +70.9% | +74.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (68.87M) USD
- Year-over-year change
- -3.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.87M) | -3.1% |
| FY2024 | 2024-12-31 | (66.81M) | -96.2% |
| FY2023 | 2023-12-31 | (34.05M) | — |
Net Income vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 net income of -$75.99M is the 6th highest of the 10 companies compared; the peer median is -$54.28M.
- Net income amounts to 759.9% of revenue for EVMN, versus a peer median of 67.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $197.22M | +360.0% | — | 67.9% | |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| LTM Mar 2026 | -$31.99M | +57.0% | — | 41.0% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$52.79M | +43.2% | — | — |
| LTM Mar 2026 | -$54.28M | +11.4% | — | 187.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | -$75.99M | — | — | 759.9% |
FTREFortrea Holdings Inc. | LTM Jun 2026 | -$85.2M | +91.7% | — | 3.2% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$87.07M | -34.3% | — | — |
| LTM Mar 2026 | -$194.97M | -211.8% | — | 129.0% | |
| LTM Mar 2026 | -$271.6M | -85.0% | — | 3566.6% | |
| Peer median (excluding EVMN) | -$54.28M | +43.2% | — | 67.9% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.